Top Back to top

Outcomes of HSCT for autoimmune cytopenias (AIC): a Retrospective Registry Study from the Autoimmune Diseases Working Party (ADWP) and the Paediatric Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Autoimmune Diseases Working Party (ADWP)
Paediatric Diseases Working Party (PDWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Auto immune disorders
Short title:
Outcomes of HSCT for autoimmune cytopenias (AIC)
Primary objective:
To establish the safety and efficacy of first or subsequent autologous or allogeneic HSCT where the disease indication is a single or multilineage primary or secondary autoimmune cytopenia (ITP, AIHA, Evans Syndrome, AIN) treated at an EBMT centre, registered in the EBMT database.
Key inclusion criteria:
- Adult and paediatric patient treated with first autologous or allogeneic HSCT for a diagnosis of primary or secondary single or multilineage autoimmune cytopenia (ITP, AIHA, Evans syndrome, AIN). (Autoimmune disorder code 10, Haematological disorders excluding autoimmune lymphoproliferative syndrome.
- Autologous or allogeneic HSCT performed for AIC from January 1997 and December 2019
Principal investigator:
Nichola Cooper
EBMT Study coordinator:
Manuela Badoglio
Study coordinator email: